NEW YORK, Nov. 19 (GenomeWeb News) - Cellular Genomics said today it has added an additional drug target to its kinase discovery collaboration with Serono.
Under the agreement, Cellular Genomics will use its Analog Sensitive Kinase Allele technology to produce modified kinases for Serono, and will use its P-inhibitor technology to study consequences of kinase inhibition in vivo and to map kinase signaling pathways for Serono.
The Brandord, Conn.-based chemical genomics company, first signed the agreement with Serono in October 2002, to apply its chemical genetics technologies to four kinase drug targets that Serono had selected. Cellular Genomics' ASKA technology consists of genetically modified kinases that act like normal kinases, but can be selectively and specifically inhibited with a small-molecule inhibitor the company has designed.
The parties did not disclose the financial terms of the agreement.